Chembio Partners With Integrated BioTherapeutics, Inc. to Develop Point-of-Care Diagnostic Tests for Ebola and Febrile Illness

MEDFORD, N.Y., Oct. 27, 2014 -- Chembio Diagnostics, Inc. (CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has entered into an exclusive agreement with Integrated BioTherapeutics, Inc. (IBT), a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. Under the terms of the agreement, Chembio will combine its patented DPP(R) technology with IBT's proprietary Ebola reagents to develop POC diagnostic tests for Ebola and febrile illness. Chembio will have exclusive rights to any POC product developed through this agreement. Financial terms of the agreement were not disclosed.

Published: 27 October 2014
Written by Editor
Nasdaq   Ebola  
Read more: Chembio Diagnostics Inc ( CEMI )

Data to be Presented at ASHG 2014 Show That Miscarriage Analysis by Chromosomal Microarray Yields a Successful Result in More Than 85% of Cases

Results Will Be Presented by Trilochan Sahoo, M.D., Director of Cytogenetics at CombiMatrix

IRVINE, Calif., Oct. 14, 2014 -- CombiMatrix Corporation (CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced data from a comprehensive, multi-year analysis of products of conception (POC) testing by chromosomal microarray analysis (CMA) showing that CMA yields a successful result in more than 85% of cases. Trilochan Sahoo, M.D., Director of cytogenetics at CombiMatrix, will present results at the American Society of Human Genetics (ASHG)'s 64th Annual Meeting on Monday, October 20, 2014 in San Diego, California.

Published: 16 October 2014
Written by Editor
Nasdaq   Project Update  
Read more: CombiMatrix Corporation ( CBMX )

Exact Sciences Announces Final National Coverage Determination for Cologuard®

CMS to cover the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer

MADISON, Wis.-- Exact Sciences Corp. (EXAS) today announced that the Centers for Medicare & Medicaid Services (CMS) issued its final National Coverage Determination (NCD) for Cologuard, making it the first and only Food and Drug Administration (FDA) approved stool DNA test for the detection of colorectal cancer and precancer covered by Medicare. Coverage will go into effect immediately. Exact Sciences is still awaiting a preliminary pricing determination from CMS.

The NCD was based on the comprehensive review by the federal government agency as part of the FDA and CMS parallel review pilot program. Cologuard is the first medical device to receive FDA approval and a final NCD as part of the parallel review process.

Published: 10 October 2014
Written by Editor
Nasdaq   Project Update  
Read more: Exact Sciences Corp ( EXAS )

CombiMatrix Reports Preliminary Growth in Prenatal Microarray Testing Volumes of 71% and 64% for the Third Quarter and Year-to-Date, Respectively

Also Reports Preliminary Record Quarter for Cash Receipts of $2 Million

IRVINE, Calif., Oct. 7, 2014  -- CombiMatrix Corporation (CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced that it expects to report record volumes of prenatal testing in the third quarter and nine months ended September 30, 2014. Preliminary growth rates of 71 percent and 64 percent are estimated for billable prenatal tests in the third quarter and year-to-date periods, respectively, compared to the comparable periods in 2013. The Company believes the growth rate in prenatal testing, which includes both prenatal and miscarriage testing, is the result of the Company's strategic shift to focus on its prenatal molecular diagnostics testing markets, where the Company believes that chromosomal microarray analysis is becoming the standard of care.

Published: 07 October 2014
Written by Editor
Nasdaq   Project Update  
Read more: CombiMatrix Corporation ( CBMX )

AMAG Pharmaceuticals to Acquire Lumara Health Maternal Health Business

  • Accelerates transformation of AMAG to a Profitable, Multi-Product Specialty Pharmaceutical Company
  • Adds FDA-Approved Therapy Makena(R) and Complementary Commercial Platform to AMAG Portfolio
  • Projected Pro Forma Combined 2015 Revenues of $350 million and Estimated Annual Cost Synergies of at least $20 million
  • Transaction Expected to be Immediately Accretive to Adjusted Earnings Per Share
  • Conference Call Today at 8am ET to Discuss Transaction
Published: 29 September 2014
Written by Editor
Nasdaq   M & A   Up on News  
Read more: AMAG Pharmaceuticals Inc ( AMAG )
  1. Trovagene Inc ( TROV )
  2. Miraculins Inc ( MOM )
  3. T2 Biosystems Inc ( TTOO )
  4. Miraculins Inc ( MOM )
  5. Quidel Corporation ( QDEL )